AAV2-mediated in vivo immune gene therapy of solid tumours by Collins, Sara A et al.
RESEARCH Open Access
AAV2-mediated in vivo immune gene therapy of
solid tumours
Sara A Collins
1,2, Alexandra Buhles
1, Martina F Scallan
2, Patrick T Harrison
3, Deirdre M O’Hanlon
4,
Gerald C O’Sullivan
1, Mark Tangney
1*
Abstract
Background: Many strategies have been adopted to unleash the potential of gene therapy for cancer, involving a
wide range of therapeutic genes delivered by various methods. Immune therapy has become one of the major
strategies adopted for cancer gene therapy and seeks to stimulate the immune system to target tumour antigens.
In this study, the feasibility of AAV2 mediated immunotherapy of growing tumours was examined, in isolation and
combined with anti-angiogenic therapy.
Methods: Immune-competent Balb/C or C57 mice bearing subcutaneous JBS fibrosarcoma or Lewis Lung
Carcinoma (LLC) tumour xenografts respectively were treated by intra-tumoural administration of AAV2 vector
encoding the immune up-regulating cytokine granulocyte macrophage-colony stimulating factor (GM-CSF) and the
co-stimulatory molecule B7-1 to subcutaneous tumours, either alone or in combination with intra-muscular (IM)
delivery of AAV2 vector encoding Nk4 14 days prior to tumour induction. Tumour growth and survival was
monitored for all animals. Cured animals were re-challenged with tumourigenic doses of the original tumour type.
In vivo cytotoxicity assays were used to investigate establishment of cell-mediated responses in treated animals.
Results: AAV2-mediated GM-CSF, B7-1 treatment resulted in a significant reduction in tumour growth and an
increase in survival in both tumour models. Cured animals were resistant to re-challenge, and induction of T cell
mediated anti-tumour responses were demonstrated. Adoptive transfer of splenocytes to naïve animals prevented
tumour establishment. Systemic production of Nk4 induced by intra-muscular (IM) delivery of Nk4 significantly
reduced subcutaneous tumour growth. However, combination of Nk4 treatment with GM-CSF, B7-1 therapy
reduced the efficacy of the immune therapy.
Conclusions: Overall, this study demonstrates the potential for in vivo AAV2 mediated immune gene therapy, and
provides data on the inter-relationship between tumour vasculature and immune cell recruitment.
Introduction
Cancer cells are capable of evading regular immune
responses for a number of reasons: they can secrete
immunosuppressive factors[ 1 ] ,t h e r ec a nb ed o w n -
regulation of antigen expression [2,3] or of major histo-
compatability complex (MHC) molecules [4,5] and also
a lack of co-stimulation [6,7]. With the advent of gene
therapy as a tool for cancer treatment, immunotherapy-
related approaches to stimulate immune responses
against cancer cells include the transfer of immune sti-
mulatory genes such as cytokines or costimulatory genes
into cancer cells, enhancing antigen presentation
through the manipulation of antigen presenting cells
(APCs) and genetic vaccination against cancer cell-
specific antigens [8,9].
AAV has a number of properties that make it an ideal
candidate as a gene delivery vector for the treatment of
cancer. AAV elicits only mild host immune responses
in vivo [10]; long term transgene expression can be
achieved [11,12] and also many of the therapeutic genes
for cancer treatment fall within the size limit dictated
for rAAV. While vectors derived from AAV have shown
great promise in the course of research into treatment
of numerous indications ranging from cystic fibrosis to
haemophilia B [13,14], only in recent years have they
begun to be investigated in a cancer setting [15-18].
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(GM-CSF) is a cytokine that acts as a critical factor for
development and differentiation of macrophages and
dendritic cells (DCs). Activation of T cells is enhanced
by local GM-CSF mediated recruitment of DCs, allow-
ing for the efficient uptake of antigens and presentation
to T cells in the draining lymph node. Co-stimulatory
molecules are essential for correct T cell activation and
subsequent differentiation into effector T cells following
their interaction with antigen presenting cells (APCs).
The initial signal for activation is dependent on specific
T cell receptor (TCR) recognition of the antigen pre-
sented by MHC molecules on APC. The second signal
is delivered through the binding of co-stimulatory mole-
cules expressed on the APC surface with their ligands
on T cells. A lack of co-stimulatory signals allows
tumour cells to induce antigen specific tolerance or
anergy on the basis of MHC class I restricted presenta-
tion [19,20]. The CD28 receptor has been identified as
one of the most important costimulatory receptors on T
cells. The ligands for this receptor are members of the
B7 family and include B7-1 (CD80) [21,22]. B7-1-trans-
duced tumour cells are expected to present both the
antigen and the co-stimulatory (CD28-mediated) signals
to CD8
+ CTL simultaneously, leading to efficient activa-
tion of CTLs without requiring the assistance of CD4
+
helper T cells. Transfection/transduction with B7-1 has
resulted in tumour cell rejection in several tumour mod-
els [19,23-26]. Studies have also demonstrated that cells
modified to express GM-CSF or B7-1 can be used to
induce protective, T cell-mediated immune responses.
Different approaches have been taken for the modifica-
tion of cells, including both ex vivo viral transduction of
leukaemia cells [27] and non-viral delivery of the genes
on plasmids to growing tumours [28].
For effective cytotoxic responses, in addition to effec-
tive education/priming of the immune system to tumour
antigens, the local tumour environment must permit
immune cell infiltration. Angiogenesis is the formation
of new capillary blood vessels from existing microvessels
which occurs in physiological and pathological states
[29]. This process is controlled by numerous angiogenic
factors that are able to attract endothelial cells from the
surrounding tissues and represents a crucial stage in
tumour growth and metastasis [29,30]. For cancer ther-
apy, strategies based on the manipulation of angiogen-
esis are referred to as anti-angiogenic strategies and
seek to prevent new vessel formation or to inactivate
pre-existing vessels. Although angiogenesis is a discrete
component of the tumour phenotype, it is often
neglected by tumour immunologists. However, lympho-
cyte extravasation is tightly controlled by blood vessels
and requires orchestration of multiple receptor-ligand
interactions as well a favourable cytokine/chemokine
micromilieu [31]. Moreover, ongoing angiogenesis
induces profound morphological and molecular changes
in tumour blood vessels and may thus contribute signifi-
cantly to the tumour’s intrinsic resistance to infiltration
by immune cells. Therefore, effective tumour immune
strategies require both fully armed effector cells and a
tumour environment permissive for infiltration and
destruction.
The invasive and metastatic behaviour of tumour cells
is regulated by extracellular growth factors like hepato-
cyte growth factor (HGF), which is a ligand for the
c-Met receptor tyrosine kinase [32,33]. HGF is a hetero-
dimeric molecule and functions of HGF include mito-
genic, motogenic, morphogenic and anti-apoptotic
activities [34,35]. In cancer, HGF stimulates malignant
cell invasion behaviour through its binding to c-Met
[32,33,36]. Nk4 (also known as IL32b) inhibits HGF-c-
Met signalling and therefore tumour metastasis [36,37].
Nk4 also has an additional, independent function, pro-
moting anti-angiogenic activities. This is achieved due
to the make up of Nk4, which consists of the N-termi-
nus of HGF, containing an N-terminal hairpin and four
kringle domains (well described anti-angiogenic mole-
cules) [38-41]. Nk4 augments anti-angiogenic activities
through the competitive inhibition of binding of angio-
genic growth factors such as VEGF, bFGF and HGF to
endothelial cells by its N-terminus [36,42,43]. Angiogen-
esis-inhibitory as well as cancer-specific apoptosis indu-
cing effects make the Nk4 gene an attractive candidate
for gene therapy of cancer.
The aim of this study was to assess AAV2 mediated
delivery of the immune stimulating genes GM-CSF and
B7-1 and Nk4 on different tumour models in vivo. Since
immunotherapy has the potential to recruit a systemic
immune response against tumour cells, and Nk4 treat-
ment is known to inhibit angiogenesis and metastatic
spread, a combination of these therapies may improve
or replace traditional treatments currently available.
Materials and methods
Vector constructs
pAAV2-MCS (Stratagene) was used to generate reporter
and therapeutic vectors and for the generation of AAV
control particles. The mammalian expression vector
pVivo1 was purchased from Invivogen (Cayla SAS,
Toulouse, France). A version of this plasmid, designated
pVivoGMCSF, B7-1, containing the murine GM-CSF
and murine B7-1 genes transcriptionally controlled from
two human glucose regulated protein (GRP) promoters
GRP94 and hamster GRP78 promoters respectively was
designed and cloning was performed on contract by
Invivogen. An AAV plasmid encoding the GM-CSF,
B7-1 expression cassette (pAAV2-GB) was constructed
by excising the expression cassette from pVivoGMCSF,
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ted fragment into NcoI and XbaI sites of pAAV-MCS
plasmid (Klenow treated). Inserts were confirmed by
sequencing (MWG Biotech). The AAV2-Luc,A A V 2 -
Nk4 and AAV-BB constructs have previously been
described [44]. All constructs used in this study are illu-
strated in Figure 1.
Vector generation
Recombinant AAV2 vectors (rAAV), AAV2-MCS,
AAV2-GB, AAV2-Nk4, AAV2-BB and AAV2-Luc were
generated using the AAV Helper-Free System (Strata-
g e n e ,A g i l e n t ,D u b l i n ) .r A A Vp a r t i c l e sw e r ep u r i f i e d
using the Virakit AAV Purification Kit (Virapur, San
Diego, USA) per manufacturer’s instructions. Purified
AAV2-GB particles were used to transduce HT1080
cells and FACS analysis for B7-1 expression employed
to determine the number of transducing units (TU).
Purified AAV2-MCS, AAV2-Nk4, AAV2-BB and AAV2-
Luc preparations were titrated using real time PCR to
determine the number of genome copies, using primers
specific for the CMV promoter (forward: 5’ aaatgggcgg-
taggcgtgta 3’, reverse: 5’ gatcggtcccggtgtcttct 3’)a n d
were synthesized by MWG Biotech, Germany. A frag-
ment of length 124 bp is expected.
Cell lines and tissue culture
Murine JBS fibrosarcoma tumour cells [28] and murine
Lewis Lung Carcinoma cells were maintained in culture at
37°C in a humidified atmosphere of 5% CO2, in Dulbecco’s
Modified Essential Medium (GIBCO, Invitrogen Corp.,
Paisley, Scotland) supplemented with 10% iron-supplemen-
ted donor calf serum (Sigma Aldrich Ireland, Ireland), 300
μg/ml L-glutamine. Cell densities were determined by
visual count using a haemocytometer. Cell viability was
confirmed by Trypan Blue Dye Exclusion (Sigma Aldrich
Ireland, Ireland) to be > 95% for tumour induction.
Human HT1080 fibrosarcoma cells were maintained in
culture at 37°C in a humidified atmosphere of 5% CO2, in
Eagle Minimum Essential Medium (GIBCO, Invitrogen
Corp., Paisley, Scotland) supplemented with 10% iron-
supplemented donor calf serum (Sigma Aldrich Ireland,
Ireland), 300 μg/ml L-glutamine.
In vitro transduction
Cells were seeded in a 12-well plate (HT1080 at 2 × 10
5,
JBS at 5 × 10
4 cells per well, LLC at 1.5 × 10
5 cells per
well) in complete medium 24 h before transduction. On
the day of transduction, cells were 80% confluent. 9 ×
10
8 genome copies (GC) of AAV2-Luc or 7 × 10
5 trans-
ducing units (TU) of AAV2-GB in a 0.5 ml volume of
transduction medium (DMEM, 2% FBS) were added to
individual wells. The plates were incubated for 2 h at
37°C, 5% CO2 with gentle rocking at 30 min intervals
during the incubation. 0.5 ml post infection medium
(DMEM, 18% FBS) was added to each well and incu-
bated at 37°C, 5% CO2 for a further 24 h.
Flow-cytometric analysis and ELISA of transduced cells
Cell surface expression of B7-1 was detected by flow
cytometry using a FACScan (Becton Dickinson, San
Jose, CA) with CD80-specific antibody, clone L307.4
(BD Biosciences UK Ltd, Oxford, UK). Briefly AAV2-GB
transduced and mock-infected cells were harvested 48 h
post transduction. The cells were labelled with the
CD80-specific antibody, an isotype control antibody F
(ab’) 2 Goat Anti Rat IgG: RPe Mouse ADS (Serotec) or
unlabeled. 10,000 events were acquired and analyzed for
PE fluorescence. PE was measured on the FL2-channel
(short band pass 575 nm filter) and plotted against side
scatter. Cells without a conjugated antibody and cells
with an irrelevant antibody conjugated antibody were
used as controls, thereby correcting for background
fluorescence.
Production of GM-CSF from JBS cells was quantified
by enzyme-linked immunosorbent assay (ELISA) (Quan-
tikine Mouse GM-CSF Immunoassay R&D Systems,
Minneapolis, MN). For quantification of GM-CSF pro-
duction in transduced cells, AAV2-GB transduced and
untransduced cell supernatant was harvested 48 h post
transduction and the assay was carried out as per the
manufacturer’s protocol.
Animals and tumour induction
Mice were obtained from Harlan Laboratories (Oxford-
shire, England), and kept at a constant room tempera-
ture (22°C) with a natural day/night light cycle in a
conventional animal colony. Standard laboratory food
and water were provided ad libitum. Before experi-
ments, mice were afforded an adaptation period of at
least 14 days. Female Balb/Co rC 5 7 B l / 6m i c ei ng o o d
condition, without fungal or other infections, weighing
ITR ITR
MCS AAV2-BB
AAV2-Nk4
SV40 pAn BGlo pAn Bsr EM7 CMV 
HindIII XhoI
CMV  BGlo intron hGH pAn
ITR ITR
SV40 pAn BGlo pAn Bsr EM7 CMV 
HindIII
XhoI
hIL32b CMV  BGlo intron hGH pAn
ITR ITR
CD80
ITR ITR
CMV  BGlo intron hGH pAn
ITR ITR
CMV  hGH pAn
AAV2-GB
AAV2-Luc
AAV2-MCS BGlo intron
Luciferase
MCS
hGRP94  EF1 pAn CMV enh
CMV 
haGRP78  GM-CSF SV40 pAn
Figure 1 Vector constructs. Schematic of coding regions of AAV2
vector constructs used in this study. AAV2-MCS: Cloning construct.
AAV2-Luc: Firefly luciferase expressing vector. AAV2-GB: Vector
encoding both GM-CSF and B7-1 genes. AAV2-BB: BackBone Vector
relating to AAV2-Nk4, lacking the discrete Nk4 coding sequence but
containing all other sequences. AAV2-Nk4: Vector encoding Nk4
sequence.
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experiments. For routine tumour induction, 2 × 10
6 JBS
cells or 5 × 10
5 LLC cells suspended in 100 μl of serum
free DMEM or were injected subcutaneously (SC) into
the flank. Following tumour establishment, tumours
were allowed develop and monitored mostly by alternate
day measurements in two dimensions using a Verniers
Callipers. Tumour volume was calculated according to
the formula V = ab
2 Π/6, where a, is the longest dia-
meter of the tumour and b is the longest diameter per-
pendicular to diameter a. From these volumes, tumour
growth curves were constructed. In cases of successful
treatment, 100 days with no recurrence was considered
a cure. In the case of recurrence, the animal was consid-
ered incurable and humanely euthanized when the
tumour diameter was between 1.5 - 2 cm. Survival time
extended from the time of first treatment to 100 days
(successful treatments) or to sacrifice (recurrences).
In vivo gene delivery
A l la n i m a le x p e r i m e n t sw e re approved by the ethics
committee of University College Cork. Mice were
randomly divided into experimental groups and subjected
to specific experimental protocols. For tumour experiments,
mice were treated as soon as the tumour could be reliably
injected (tumour diameter = 0.4 cm on average). For quad-
riceps muscle experiments, a single intramuscular injection
was carried out into the right or left thigh of the animal.
Mice were anaesthetized during all treatments by intraperi-
toneal (IP) administration of 200 μg xylazine and 2 mg
ketamine. Viral vector particles were administered by direct
intratumoural (IT) or intramuscular injection (IM) in a
volume of 50 μl2×1 0
8 -2×1 0
9 GC of replication incom-
petent recombinant AAV2 particles.
In vivo confirmation of Nk4 gene delivery and expression
Muscle tissue from animals treated by IM injection of
AAV2-Nk4 and untreated animals was excised at day 3.
T h em u s c l et i s s u ew a sp a s s e dt h r o u g han y l o nm e m -
brane in order to disassociate the tissue and create a
single cell suspension. The cells were precipitated by
centrifugation, the DNA and RNA was simultaneously
extracted from the cell pellet using the Qiagen Allprep
DNA/RNA kit as per the manufacturers protocol. DNA
and RNA concentration was determined using the nano-
drop. AAV mediated delivery was confirmed by PCR
and AAV mediated gene expression was confirmed by
rtPCR. The primers were against the Nk4 sequence For-
ward: 5’CCTCTCTGATGACATGAAGAAG 3’, Reverse:
5’TGTCACAAAAGCTCTCCCC 3’. PCR conditions
were as follows HotstarTaq Activation 95°C-15 min,
Denaturation 94°C-1 min, Annealing 59°C -1 min, Elon-
gation 72°C-1 min. Nk4 DNA was detected by PCR in
50 ng of DNA using HotstarTaq Master Mix Kit
(Qiagen) in a Mastercycler (Eppendorf,, UK) PCR
machine. The PCR products were visualised on a 1%
agarose gel. Nk4 expression of transduced muscle was
confirmed by rtPCR. Extracted RNA was DNAse treated
using Ambion DNAfree kit according to manufacturer’s
instructions. RNA concentration was determined using
the nanodrop. Omniscript RT kit (Qiagen) was used to
generate cDNA from 100 ng of total RNA in a 20 μl
volume according to manufacturer’s instructions. The
cDNA was diluted to a final volume of 50 μl following
cDNA synthesis using DNasefree H2O. 5 μld i l u t e d
cDNA was PCR amplified using HotstarTaq Master Mix
Kit (Qiagen) in a Mastercycler (Eppendorf, UK) PCR
machine. The PCR products were then visualised on a
1% agarose gel.
Luminescence measurements
For in vitro experiments, treated cells were analysed for
luciferase activity 48 h post transduction using the Luci-
ferase Assay System (Promega MSC, Dublin), as per
manufacturer’s instructions. Luminescence was mea-
sured using the IVIS Imaging System (Xenogen, UK).
In vivo luciferase activity from tissues was analysed
post- transduction as follows: 80 μlo f3 0m g / m lf i r e f l y
luciferin (Biosynth, Basil, Switzerland) was injected
intraperitoneally (IP) and intratumourally (IT). Mice
were anaesthetised as before. Ten minutes post-luciferin
injection, live anaesthetised mice were imaged for 3 min
at high sensitivity using the IVIS imaging system (Xeno-
gen, UK).
In vivo cytotoxicity assay
The development of an immune-mediated anti-tumoural
activity following treatment was tested by in vivo cyto-
toxicity assay [45]. The Winn assay was utilised as fol-
lows: mice (six/group) received injections of a mixture
of JBS cells and splenocytes from either AAV2-GB
cured mice or naive mice. Splenocytes were taken 100
days post tumour regression from ‘cured’ mice for use
in Winn assays. Splenocytes were mixed with tumour
cells and injected SC in a proportion of 50:1 (10
8 spleen
cells to 2 × 10
6 JBS cells). Mice were then monitored on
alternate days for tumour development.
Statistical Analysis
T h ep r i m a r yo u t c o m ev a r i a b l eo ft h es t a t i s t i c a la n a l y s e s
was the tumour volume in each mouse measured at
each time point. The principal explanatory variables
were the different treatment groups. Tumour volume
was analyzed as continuous. Treatment groups were
analyzed as categorical variables. At each time point, a
two-sampled t-test was used to compare mean tumour
volume within each treatment group depending on the
number of groups being compared. Microsoft Excel 11.0
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Prism Software Inc, San Diego, CA, USA) were used to
manage and analyze data. Statistical significance was
d e f i n e da tt h es t a n d a r d5 %l e v e l .S u r v i v a lw a sa n a l y s e d
using a two-sampled Student’s t-test assuming equal
variances to compare the average number of days sur-
vived per group.
Results
Validation of vector constructs and gene expression
Flow Cytometric analysis of cell surface expression of
B7-1 and ELISA for GM-CSF confirmed the functional-
ity of AAV2-GB particles in vitro. The human HT1080
fibrosarcoma cell line was used, being the standard cell
line for AAV transduction assays. HT1080 cells were
transduced with AAV2-GB or mock transduced with
PBS. After 48 h, cells and supernatant were harvested
for assays. Cells were labelled with anti-CD80 antibody,
and the resulting overlay graph (Figure 2a) demon-
strated an increase of 38.2% in B7-1 expression in trans-
duced cells (light grey overlay peak) in comparison cells
labelled with an isotype (dark grey peak). GM-CSF pro-
tein was detected in cell culture supernatant in cells
transduced with AAV2-GB at a level of 250 pg/ml and
not in mock-infected cells (Figure 2b).
The efficiency of AAV2 mediated transduction of each
of the test cell lines was determined in cells transduced
with either AAV2-GB or AAV2-Luc particles. FACS ana-
lysis for cell surface expression of B7-1 confirmed trans-
duction of both JBS (Figure 2c) and LLC (Figure 2d).
These graphs demonstrate that JBS cells (13.4% increase)
a r em o r ep e r m i s s i v et ot r a nsduction with AAV2 than
LLC cells (4.25% increase). Also evident from these data
is that there is a low level of endogenous cell surface
B7-1 expression in untreated LLC cells, which has also
been reported by other groups [46]. A lower level of
background B7-1 expression was observed in JBS cells.
The efficiency of AAV2 mediated transduction of
growing JBS and LLC tumours was also assessed.
AAV2-Luc was administered IT to SC tumours and luci-
ferase expression assessed using the IVIS system on day
7-post administration. Luminescence was detected in
JBS tumours in Balb/C mice at 9.7 × 10
-1 p/sec/cm
2/sr/
gene copy administered (Figure 2g) and in LLC tumours
in C57Bl/6 mice at 1.64 × 10
-8 p/sec/cm
2/sr/gene copy
administered (Figure 2g). In order to confirm transgene
expression from AAV2-GB transduced tumours in vivo,
LLC tumours were excised 7 days after IT delivery of
AAV2-GB or PBS. Cell surface expression of B7-1 was
detected by flow cytometry as previously described.
Results indicated that administration of AAV2-GB
resulted in an increase in cell surface B7-1 expression. A
background level of B7-1 expression of approximately
10% was seen in PBS treated LLC cells while a 5.2% (+/-
1.48) increase in B7-1 positive cells was observed in
AAV2-GB transduced LLC cells (Figure 2f).
AAV mediated immune gene therapy of tumours in vivo
The AAV2-GB construct was used to deliver GM-CSF
and B7-1 to JBS or LLC tumours. The JBS study con-
sisted of three groups (n = 5): an AAV2-GB treated
group, an AAV2 null vector treated group (AAV2-Luc
vector), and an untreated group. The tumour growth
curve (Figure 3a) illustrates a significant decrease in
tumour growth rate in those groups treated with AAV
particles expressing GM-CSF and B7-1 genes in compar-
ison with untreated and null vector treatment groups.
There was a significant reduction in tumour growth on
day 21 between the AAV2-GB treated group and the
null vector treatment group (p = 0.028), confirming that
tumour regression involved the therapeutic genes
encoded by the particles and was not due to a response
to the particle alone. The survival curve (Figure 3b)
illustrates a significant increase in survival for all mice
treated with GM-CSF, B7-1 in comparison with the
untreated controls (p < 0.0008). The treatment resulted
in a cure for 60% of the treated animals.
The LLC study consisted of three groups (n = 6): an
untreated control group, an AAV null vector (AAV2-
BB) group and an AAV2-GB treated group. The tumour
growth curve (Figure 3c) illustrates a marked decrease
in tumour growth in the AAV2-GB treated group in
comparison with the untreated and null vector controls.
The reduction in tumour growth was significant on days
20 - 27 (p < 0.02) between AAV2-GB treated mice and
both the untreated and null vector groups. There was
no significant difference between the untreated and the
null vector groups. The survival curve (Figure 3d) illu-
strated a significant increase in survival in animals trea-
ted with GM-CSF, B7-1 in comparison with the
untreated and null vector groups. Although the increase
in survival was significant (p = 0.008), the therapy did
not result in cure in any of the treated animals.
Immunological memory following tumour treatment
In cases where complete tumour regression occurred
(60% JBS treated mice), ‘cured’ mice were rechallenged
to assess for sustained anti-tumoural immunological
responses. Mice were injected SC on the opposite flank
to the original tumour challenge, with tumourigenic
doses of the same tumour type (JBS) 30 days following
tumour regression. AAV2-GB ’cured’ mice remained
tumour free to 100 days whilst all naïve mice developed
tumours and were culled due to tumour burden by day
28 (Figure 3e), indicating immunological memory to
tumour antigens.
In order to examine for a cell-mediated immune
response as a result of AAV2-GB treatment, the
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Figure 2 Validation of immune gene vector construct and transduction efficiency. (a-b) Gene Expression from AAV2-GB. FACS Analysis and
ELISA for GM-CSF were used to determine the functionality of AAV2-GB particles in vitro. A 38.2% (+/- 7.4) increase in B7-1 positive cells was
observed in AAV2-GB transduced JBS cells. GM-CSF protein was detected in cell culture supernatant in cells transduced with AAV2-GB at a level
of 250 pg/ml. (c-e) Transduction of JBS and LLC cells in vitro. The efficiency of AAV2 mediated transduction of the test cell lines JBS and LLC was
determined using FACS analysis for cell surface B7-1 expression following AAV2-GB transduction or by luciferase assay following AAV2-Luc
transduction. (c) A background level of B7-1 expression of approximately 5% was seen in PBS treated JBS cells while a 13.4% (+/- 0.2) increase in
B7-1 positive cells was observed in AAV2-GB transduced JBS cells. (d) A background level of B7-1 expression of 9.4% was observed in PBS
treated LLC cells while a 4.25% (+/- 0.15) increase in B7-1 positive cells was observed in AAV2-GB transduced LLC cells. (e) Luminescence was
readily detected in both JBS and LLC cells with a significantly higher level evident in JBS cells (p = 0.004). (* Statistical significance (p < 0.05)).
(f) Transduction of LLC in vivo with AAV2-GB. A background level of B7-1 expression of approximately 10% was seen in PBS treated LLC cells
while a 5.2% (+/- 1.48) increase in B7-1 positive cells was observed in AAV2-GB transduced LLC cells. (g) Transduction of JBS and LLC in vivo with
AAV2-Luc. IVIS imaging confirmed AAV transduction of JBS tumours in vivo (9.7 × 10
-1 p/sec/cm
2/sr/gene copy administered, +/- 0.27) and LLC
tumours (4.3 × 10
-3 p/sec/cm
2/sr/gene copy administered, +/- 0.0009).
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Figure 3 Immune therapy of tumours in vivo. (a-b) Effect of AAV2 delivered GM-CSF, B7-1 on SC JBS fibrosarcoma growth in vivo.
(a) Representative growth curve of JBS tumours treated with AAV2-GB particles or null vector (AAV2-Luc) or untreated. There was a significant
difference (p vs. null vector = 0.028, vs. untreated = 0.017) in tumour volume at day 21 between the tumours transduced with AAV2-GB and
control tumours. (b) Approximately 66% animals treated with AAV2-GB survived 100 days post treatment, with no signs of tumour recurrence.
Treatment with null vector resulted in a slight improvement in survival, but this did not approach significance. (c-d) Effect of AAV2 delivered
GM-CSF, B7-1 on SC LLC tumour growth in vivo. Established LLC tumours were treated by IT administration of AAV2-GB or AAV-MCS (control) or
no particles (PBS) and growth and survival monitored. (c) Tumour volumes in the AAV2-GB group were significantly reduced (p < 0.03) when
compared with the AAV2-BB administered control group and the untreated group. (d) Animal survival in the AAV2-GB group was significantly
(p = 0.036) increased when compared with the AAV2-MCS injected control group and the untreated group. (e-f) Immunological memory
following tumour treatment. (e) ‘JBS cured’ mice (those that had regression of JBS tumour) received a tumourogenic dose of JBS cells on the
opposite flank to the original, ‘cured’ JBS tumour. 100% cured animals receiving JBS displayed no tumour growth, while 0% of JBS naïve controls
survived beyond 30 days. (f) In vivo cytotoxicity assay. Mice received injections of a mixture of JBS cells and splenocytes from either AAV2-GB
’cured’ mice or naïve mice. All mice receiving splenocytes from ‘cured’ mice failed to grow tumours, while JBS tumours developed in all control
animals receiving splenocytes from naïve mice. (* Statistical significance (p < 0.05))
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Page 7 of 13cytotoxic activity of lymphocytes from treated mice was
examined in vivo using a modified Winn assay [45].
Groups of mice received injections of a mixture of a
tumourigenic dose of JBS cells and splenocytes from
either AAV2-GB cured mice or naïve mice. All mice
receiving splenocytes from ‘cured’ mice failed to grow
tumours, while JBS tumours developed in all control
animals receiving splenocytes from naïve mice (Figure
3f), indicating adoptive transfer to naïve mice of anti-
tumour lymphocytes conferring resistance to further
tumour challenge.
Nk4 therapy of growing subcutaneous LLC tumours
AAV2 vector mediated transgene expression is known
to be delayed initially before increasing over time
[47-49]. Given the short therapeutic window available
with the fast growing LLC tumour model, and since the
Nk4 transgene product is secreted by transduced cells,
we opted to administer AAV2-Nk4 prior to tumour
induction, to quadriceps muscle, with the aim of produ-
cing systemic circulating Nk4 protein. The temporal
pattern of AAV2-mediated expression from quadriceps
was examined using AAV2-Luc (Figure 4a). Expression
was observed to increase up to day 14 and remain
higher thereafter.
For tumour experiments, quadriceps muscles were
transduced with AAV2-Nk4 14 days prior to LLC
tumour induction and tumour growth monitored on
alternate days (Figure 4c). Nk4 delivery and expression
was confirmed by PCR (Figure 4b). For animals treated
with AAV2-Nk4 there was a significant reduction in
tumour growth compared with the untreated group (p =
0.048 on day 20), although this significance was not
seen when compared with the null vector treated group.
The Kaplan-Meier curve (Figure 4d) illustrates an
increase in survival in animals treated with Nk4,
although not reaching statistical significance in compari-
son with the untreated (p = 0.06) or null vector groups
(p = 0.26).
Combination of immune and anti-angiogenic therapies
In an effort to enhance both the immune and Nk4 pro-
tocols, a combined therapy was examined. The study
consisted of 5 groups: an IT AAV2-GB/IM AAV2-BB
treated group, an IT AAV2-MCS/IM AAV2-Nk4 treated
group, a combined IT AAV2-GB/IM AAV2-Nk4 treated
group, an IT AAV2-MCS/IM AAV2-BB treated group
(null vector), and an untreated group. The tumour
growth curve (Figure 4e) again illustrates a marked
decrease in tumour growth in groups treated with AAV
expressing GM-CSF, B7-1 or Nk4 genes alone in com-
parison with the untreated and null vector groups. How-
ever, treatment with AAV2-Nk4 prior to immune
therapy, eliminated the anti-tumour effects of AAV2-GB
treatment (Figure 4e), with tumour growth in this group
similar to controls (p vs. untreated p = 0.52, p vs. null
vector control p = 0.38).
Discussion
Though certain viral vectors can elicit strong immune
responses and systemic toxicity [50], gene transduction
efficiency is extremely high. While non-viral delivery of
plasmid DNA displays lower toxicity, a major obstacle
that has prevented its widespread application is its rela-
tive inefficiency in gene transfection [51]. The construct
used in this study encoded GM-CSF and B7-1,a n dw a s
designed such that GM-CSF would be secreted from the
tumour cell with B7-1 expressed on the cell surface in an
effort to elicit an anti-tumour immune response. We
have previously demonstrated that non-viral delivery of
these immune genes on a plasmid to JBS tumours leads
to immune stimulation and consequent eradication of
the treated tumour and associated metastases, when
delivered by electroporation [28,52] or sonoporation [53].
Other work from our laboratory has shown that
AAV2 mediated reporter gene expression in JBS
tumours is significantly higher and more sustained
than plasmid-mediated delivery. We decided to exam-
ine if the anti-tumour efficacy of GM-CSF, B7-1 could
be improved by AAV2 delivery. The results achieved
here were comparable with those observed with both
non-viral strategies, suggesting that levels of immune
gene expression may not be the limiting factor in
recruitment of anti-tumour responses. However, it
should be noted that a different temporal pattern of
transgene expression is observed with AAV and plas-
mid vectors. Gene expression from plasmid vector is
maximal 24 - 48 h post transfection, while AAV2
related transcription is delayed, taking 4 - 7 days to
surpass plasmid levels. Given the relatively short win-
dow of therapeutic opportunity permitted by the mur-
ine tumour models used here, it is plausible that
superior effects might be observed in clinical situa-
tions, where patient tumour growth is slower, thereby
facilitating AAV vector transcription levels to reach
full capacity [8,47-49]. Also, the range of patient
tumour locations and sizes amenable to AAV vector
administration is far wider than is practical for delivery
involving electroporation or sonoporation equipment,
which are currently useful only for accessible subcuta-
neous tumours. Furthermore, the potential for specific
transduction of tumour cells following systemic admin-
istration of viruses has been validated, involving the
inclusion of tumour specific targeting ligands to viral
vector surfaces [54,55].
Our studies demonstrated that the observed tumour
reductions were immune mediated, and that the
immune response induced was, at least in part, T cell
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Page 9 of 13mediated. Adoptive transfer of the anti-tumour immune
response to naïve animals prevented tumour establish-
ment. The immune gene therapy was less effective in
LLC than JBS and this might be attributed to a number
of different reasons. Both of the tumour cell lines can
be described as weakly or non-immunogenic. The JBS
murine fibrosarcoma is derived from the 3T3 cell line
and is described previously [56]. JBS grows in immuno-
competent Balb/C at the same rate as in athymic mice,
and vaccination strategies, using a diversity of
approaches, schedules and cell treatments, failed to pro-
tect Balb/C mice from subsequent tumourogenic JBS
challenges [28,56]. The well characterised LLC cell line
has previously been shown to be weakly or non-
immunogenic, with a number of approaches such as UV
irradiation [57] or viral infection [58] being used to
increase their immunogenicity in previous studies. As
demonstrated both in vitro and in vivo, AAV2 trans-
duces JBS cells more efficiently than LLC. The AAV2/2
serotype used in our studies has a reported 30% effi-
ciency of transducing LLC in vitro [59]. We observed an
even lower efficiency (data not shown). Different sero-
types such as AAV2/5 have a 65% transduction effi-
ciency in LLC [59]. Also, as demonstrated here, LLC
cells have an endogenous B7-1 expression. It is possible
that low level B7-1 expression following transduction
with AAV-GB in LLC cells could result in preferential
b i n d i n go fB 7 - 1t oC T L A - 4o nT r e gc e l l sr a t h e rt h a n
CD80 on effector cells resulting in a subsequent tumour
growth advantage, as demonstrated by Tirapu et al [46].
However, such an effect was not apparent in our studies,
with the moderate increase in CD80 expression com-
bined with GM-CSF through gene transduction suffi-
cient to significantly reduce tumour growth. An increase
in cell surface B7-1 expression breaks the immune toler-
ance allowing B7-1 to bind preferentially to its main
receptor CD28 on antigen presenting cells (rather than
Treg) creating an anti-tumour response. We have pre-
viously demonstrated that simultaneous depletion of
Treg further improves immune therapy [60].
For both tumour types examined here, it is plausible that
a minimal threshold of the percentage of tumour cells
expressing GM-CSF and B7-1 is necessary for this system
to effect complete tumour regression. Intratumoural distri-
bution of transduced cells could also be important. In
AAV2 treatment, it is likely that a large portion of the
tumour is untransduced, as the transduction region is lim-
ited to the needle track. In an attempt to maximise trans-
duction efficiency, we used multiple injections of AAV2
vector in an attempt to saturate the tumour with vector
solution. This notwithstanding, it is unlikely that there is a
requirement for transduction of every tumour cell, as the
mechanism of tumour regression is immune mediated,
whereby targeting of non-transduced tumour cells is
achieved after the gene therapy induced immune
sensitisation.
Due to the nature of the AAV2-Nk4 construct, a null
vector that encoded the blastocidin antibiotic resistance
gene was used as a control. In contrast, the AAV2-GB
construct includes no extra coding sequences. In this
case, the control vector/s used included the AAV2-MCS
or AAV2-Luc. Firefly luciferase is generally accepted to
be non-immunogenic [61], and was used here for moni-
toring of vector-mediated expression in tumours during
experiments. Specifically in relation to JBS tumours,
growth curves also illustrate that there is a moderate,
but statistically insignificant reduction in tumour growth
for those tumours treated with the null vector (AAV2-
Luc) in comparison with the untreated group. No such
tumour reduction in tumour growth was seen in LLC
tumours treated with the null vector (AAV2-BB) in
comparison with the untreated LLC group.
In this study, we also assessed the effects on tumour
growth of combining anti-angiogenic treatment with
immune gene therapy. The process of angiogenesis pro-
vides an ideal target for treatment, has been studied exten-
sively and anti-angiogenic agents are in clinical use [62].
Solid tumours create a unique microenvironment, featur-
ing chaotic vasculature, resulting in zones of tumour
ischaemia and poor intratumoural circulation, which can
prevent immune cell access [31,63-65]. In recent years,
evidence is accumulating that the immune and vascular
environments are closely linked. Several studies have indi-
cated that vascular components of the tumour stroma are
targeted during immune-mediated tumour rejection [31].
Furthermore, recent reports indicate that certain anti-
angiogenic therapies, rather than eliminating vasculature
in the tumour and ‘starving’ cells, serve to normalise
microcirculatory function, permitting access to the tumour
for immune cells [63]. By developing a deeper understand-
ing of the activity in vivo of various anti-angiogenic agents,
new improved therapeutic regimes may be developed by
addressing simultaneous anti-angiogenic activity and
immune up-regulation, with more therapeutic potential
than either therapeutic approach alone. We have pre-
viously shown that IT administered AAV2-Nk4 did not
significantly reduce SC LLC tumour growth [44]. In the
current study, systemic production of Nk4 induced prior
to tumour establishment provided superior anti-tumour
immune responses to IT delivery, with a reduction in
t u m o u rb u r d e na n da ni n c r e a s ei ns u r v i v a li nA A V - Nk4
treated animals, although differences were not statistically
significant. However, the combination studies described
here showed that Nk4 therapy eliminated the efficacy of
the immune therapy. In our experiments involving prior
expression of anti-angiogenic agent, it is possible that Nk4
mediated reduction in tumour neovasculature may act as
an obstacle to immune therapy by preventing migration of
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[31,64,65]. The schedule and timing of combined treat-
ment may be key in achieving improved responses with
such an approach. In addition, since Nk4 is a multifunc-
tional molecule, we cannot rule out the possibility that its
activity other than anti-angiogenic, might play a role in
the observed responses. The design of the experiment
addressed the possibility that pre-exposure to the first
AAV vector IM precluded gene transfer with the IT vector
one week later due to any potential immune response to
the vector. The experimental group that received AAV2-
GB IT also received AAV-BB IM one week previously, and
a significant reduction in tumour growth was still
observed, ruling out an immune reaction to AAV prevent-
ing expression of the immune genes. Furthermore, as indi-
cated in Figure 4a, IM delivery of AAV2-Luc resulted in
long-term gene expression indicating the absence of
immune responses to AAV-transduced muscle cells.
Much study is required with respect to elucidating the
complex cascade of events that is needed to reduce
angiogenesis while permitting effector cell entry into
tumours. Researching these mechanisms will enable can-
cer biologists to specifically target the tumour environ-
ment and further improve therapeutic efficacies.
Together with overcoming the obstacle of inefficient
effector cell generation in cancer patients, ‘angio-
immuno’ therapy may provide new opportunities to per-
mit tumour infiltration and destruction. Exploiting the
benefits of gene therapy, especially utilising viral vectors
such as AAV, in terms of local activity and duration of
therapeutic activity, may overcome current obstacles to
successful cancer treatment with systemically adminis-
tered drugs.
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